Obeticholic acid as a second-line treatment for low phospholipid-associated cholelithiasis syndrome.

Pierre-Antoine SoretSara LemoinneMaxime MalletKarima Ben BelkacemOlivier ChazouillèresChristophe Corpechot

Published in: Alimentary pharmacology & therapeutics (2023)

These preliminary observations suggest that OCA may have the potential to effectively treat LPAC syndrome in patients with inadequate response or intolerance to UDCA. Larger studies are needed to confirm these data.

Keyphrases

case report
combination therapy
machine learning
climate change
deep learning
replacement therapy
data analysis